SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease has been accepted for a late breaking poster presentation at the American Thoracic Society... Read More

Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab -experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo.... Read More

SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received a letter (the “Letter”) on April 18, 2024 from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it failed to maintain the continued listing... Read More

In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a 90% reduction in their EASI score (EASI-90) after 16 weeks. 56% (5/9) of patients with prior inadequate response to dupilumab achieved EASI-90 and 56% (5/9) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks. Topline, unblinded data from the full dataset expected at the end... Read More

SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give a virtual company presentation at the 2 nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions... Read More

SAN MATEO, Calif. and SINGAPORE, March 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced today announced that it has entered into a definitive agreement for the purchase and sale of 5,000,000 of the Company’s American Depositary Shares (“ADSs”), each ADS... Read More

TREK-DX, the first randomized, double-blind, placebo-controlled study to be conducted in a dupilumab -experienced atopic dermatitis (AD) patient population, has started enrolling patients in the US under an updated protocol; new European sites are on track to open in the first half of 2024 In a preliminary review of blinded data from 22 patients treated to date, 45% (10/22) of patients saw at least a 90% reduction in their... Read More

New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrations Leading respiratory experts, Ramaswamy Krishnan, PhD, and Reynold Panettieri, MD, appointed as scientific advisors to provide strategic counsel on eblasakimab ’s differentiation for... Read More

New Composition of Matter Patent for farudodstat would strengthen intellectual property protection and provide commercial exclusivity for farudodstat until at least 2043 SAN MATEO, Calif. and SINGAPORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced... Read More

SAN MATEO, Calif. and SINGAPORE, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) ("ASLAN" or the "Company"), announced today that on January 5, 2024, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the US$1.00 minimum bid price requirement under the Nasdaq Listing Rules... Read More

SAN MATEO, Calif. and SINGAPORE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its participation in upcoming conferences for January 2024. Listed below are meetings that management will be attending around the week of the J.P. Morgan 42 nd Annual... Read More

Following the successful TREK-AD Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, process is underway to identify potential partners. Recruitment in TREK-DX, studying eblasakimab in dupilumab -experienced patients, using updated criteria based on findings from TREK-AD, has commenced at US sites, with additional sites in Europe expected to open in the first half of 2024. Review of blinded safety data... Read More

SAN MATEO, Calif. and SINGAPORE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in a fireside discussion at the Piper Sandler Healthcare Conference. The conference will be held from November 28 to 30, 2023, in-person at... Read More

Head-to-head study between eblasakimab and dupilumab in skin biopsies from atopic dermatitis (AD) patients confirm eblasakimab ’s differentiated effects of targeting IL-13R vs IL-4R Using an established COPD model of human lung slices, new data demonstrate eblasakimab ’s potential to reduce airway constriction and enhance dilation Results demonstrate for the first time the potential utility of eblasakimab in other... Read More

Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis , met the primary endpoint across three dosing arms; the study established eblasakimab’s potential to deliver a monthly dosing regimen from initiation with a competitive efficacy profile. Preparations underway for the advancement of eblasakimab into Phase 3 clinical development in 2024. Topline interim... Read More

Discussion featuring KOLs Dr Jonathan Silverberg, Dr April W. Armstrong, and a leading CRO will explore “The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has Changed in the Seven Years Following Dupilumab’s Introduction” ASLAN management will present additional analyses from the TREK-AD study and new market research from prescriber and patient surveys on the AD treatment landscape... Read More

ASLAN management will present emerging data from the TREK-AD study and new market research data on the AD treatment landscape from patient and prescriber surveys Register here to attend the webinar event on October 24, 2023 at 11:00 am ET SAN MATEO, Calif. and SINGAPORE, Oct. 18, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative... Read More

Data presented during the late-breaker oral presentation of the TREK-AD study demonstrate e blasakimab’s potential as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation New data from a post-hoc analysis of patients with severe disease (baseline EASI score at least 21), representing 63% of ITT patients, show monthly dosing with 600... Read More

SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that four abstracts on eblasakimab and farudodstat have been accepted for e-poster and oral presentations at the 32 nd European Academy of Dermatology and Venereology (EADV),... Read More

SAN MATEO, Calif. and SINGAPORE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give an in-person company presentation at the H.C. Wainwright 25th Annual Global Investment Conference, to be held both virtually and in-person at the... Read More

Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab that met the primary endpoint across three dose arms with statistical significance. The data established eblasakimab , a potential first-in-class antibody, as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation Data supports advancement of... Read More

Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation comparable to once every two weeks, supporting advancement to Phase 3. 600mg eblasakimab dosed once every four weeks in the TREK-AD study met the primary endpoint with statistical significance, with 62.7% of patients achieving EASI-75, 34.1% reaching EASI-90 and... Read More

SAN MATEO, Calif. and SINGAPORE, July 05, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, will host a webcast to discuss the topline data from the global Phase 2b TREK-AD trial of eblasakimab in patients with moderate-to-severe atopic dermatitis on July 6, 2023, at 8:30... Read More

SAN MATEO, Calif. and SINGAPORE, June 23, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the publication of data from the Phase 1a single ascending dose study of eblasakimab, a monoclonal antibody targeting the IL-13 receptor subunit of the Type 2... Read More

ASLAN will receive up to $15 million in upfront and near-term payments and up to an additional $123.5 million based on development and commercial milestones plus tiered royalties on sales in percentages ranging up to low twenties Zenyaku Kogyo, a leading Japanese pharmaceutical company specializing in dermatology and oncology, plans to initiate a Phase 1 study of eblasakimab in Japan in the first half of 2024 Topline data... Read More

SAN MATEO, Calif. and SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will present a company update at the Jefferies Global Healthcare Conference, to be held in-person in New York, NY, from June 7 to 9, 2023. Presentation details... Read More

The Phase 2a, proof-of-concept study, called FAST-AA ( FArudodstat STudy in Alopecia Areata), will enroll approximately 60 adult patients in the US; interim topline readout is expected in 1Q 2024 Farudodstat is a potent, oral DHODH inhibitor with the potential to be a novel, first-in-class treatment for alopecia areata (AA) SAN MATEO, Calif. and SINGAPORE, May 18, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:... Read More

First study comparing blockade of the IL-4 receptor and IL-13 receptor, both components of the Type 2 receptor complex, presented in an oral late-breaking mini-symposium, revealed that IL-13Rα 1 blockade with eblasakimab may lead to more potent control of the Th2 inflammatory response and dampening of Th1 proinflammatory cytokines in vitro compared to blockade of IL-4Rα in patients with moderate-to-severe atopic dermatitis... Read More

Data readout for TREK-AD Phase 2b study of eblasakimab on track for early July 2023 Four abstracts on eblasakimab and farudodstat, including two late-breakers, to be presented at the 1 st International Societies of Investigative Dermatology meeting May 10-13 in Tokyo $20 million private placement led by BVF Partners with the potential to receive up to an additional $80 million if all warrants are exercised in full Company... Read More

Late-breaking abstract on the differences between IL-13Rα1 and IL4R blockade on Type 2 and Type 1 signaling in atopic dermatitis (AD) accepted for oral presentation and late-breaking abstract on role of farudodstat in human model of alopecia areata accepted for poster presentation Abstracts of the two additional poster presentations at ISID have been published online in the Journal of Investigative Dermatology Subgroup... Read More

SAN MATEO, Calif. and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company regained compliance with the minimum bid price requirement under Nasdaq... Read More

TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023 Phase 2 proof-of-concept trial of farudodstat in alopecia areata expected to commence in the second quarter of 2023 with topline data readout expected in the first quarter of 2024 Expected cash runway extended through at least the second quarter of 2024 with recent $20 million in financing, with potential to receive up an... Read More

SAN MATEO, Calif. and SINGAPORE, March 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will be available for one-on-one meetings and participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference... Read More

SAN MATEO, Calif. and SINGAPORE, March 14, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that two abstracts on eblasakimab have been accepted for poster presentation at the 1st International Societies for Investigative Dermatology Meeting, taking place from May... Read More

SAN MATEO, Calif. and SINGAPORE, March 10, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares (“ADSs”) to its ordinary shares, par value $0.01 per share, from one (1) ADS representing five... Read More

SAN MATEO, Calif. and SINGAPORE, March 08, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will be hosting a virtual research and development day on Thursday, March 16, 2023, from 10:00 am – 11:30 am ET. The event will feature Key Opinion Leader (KOL) Brett... Read More

Alopecia areata (AA) is a common autoimmune disease affecting over 700,000 patients in the US and is driven by loss of immune privilege (IP) in the hair follicles and subsequent attack by IFNγ-secreting immune cells Farudodstat is a potent, oral DHODH inhibitor which has been shown to inhibit IFNγ secretion, reduce immune cell proliferation, and potentially protect from IP collapse in a human AA disease model A Phase 2... Read More

ASLAN to receive $20 million in financing with the potential to receive up to an additional $80 million for an aggregate of $100 million to continue advancing the clinical development of eblasakimab and farudodstat ASLAN’s expected cash runway extended through at least the second quarter of 2024, and potentially further in accordance with additional warrants exercisable following topline data readouts from the TREK-AD study... Read More

The TRials with E blasaKimab in Atopic Dermatitis (TREK-AD) study has enrolled the final patient Topline results expected in early July 2023 SAN MATEO, Calif. and SINGAPORE, Feb. 24, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has enrolled the... Read More

Thermo Fisher Scientific to provide biologic manufacturing expertise and scale-up capacity to manage the clinical supply of eblasakimab for future Phase 3 studie s A high concentration formulation of eblasakimab (200mg/ml) will be manufactured which could enable doses of up to 400mg eblasakimab to be delivered via a single subcutaneous injection SAN MATEO, Calif. and SINGAPORE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ASLAN... Read More

SAN MATEO, Calif. and SINGAPORE, Dec. 16, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the Company’s participation in upcoming conferences for January 2023. Listed below are meetings that management will be attending around the week of the J.P. Morgan 41 st... Read More

The TRials with EblasaKimab in Dupilumab eXperienced atopic dermatitis patients (TREK-DX) study will evaluate eblasakimab in a patient population with few safe treatment options The study will enroll 75 patients in North America with topline results expected in the first quarter of 2024 Study is fully funded with no impact on previously reported cash runway Data from TREK-DX and TREK-AD could support the use of eblasakimab... Read More